Identification of a de novo variant in CHUK in a patient with an EEC/AEC syndrome‐like phenotype and hypogammaglobulinemia. Issue 7 (17th May 2017)

• Record Type: Journal Article
• Authors: Khandelwal, Kriti D.; Ockeloen, Charlotte W.; Venselaar, Hanka; Boulanger, Cécile; Brichard, Bénédicte; Sokal, Etienne; Pfundt, Rolph; Rinne, Tuula; van Beusekom, Ellen; Bloemen, Marjon; Vriend, Gerrit; Revencu, Nicole; Carels, Carine E. L.; van Bokhoven, Hans; Zhou, Huiqing
• Is Part Of: American journal of medical genetics. Volume 173:Issue 7(2017)
• Page Start: 1813
• Page End: 1820
• Publication Date: 2017-05-17
• Subjects: AEC -- Bartsocas–Papas syndrome -- CHUK -- cocoon syndrome -- ectodermal dysplasia -- EEC; Medical genetics -- Periodicals; 616.14205
• DOI: 10.1002/ajmg.a.38274
• Languages: English
• ISSNs: 1552-4825

Abstract

Abstract : The cardinal features of Ectrodactyly, Ectodermal dysplasia, Cleft lip/palate (EEC), and Ankyloblepharon‐Ectodermal defects‐Cleft lip/palate (AEC) syndromes are ectodermal dysplasia (ED), orofacial clefting, and limb anomalies. EEC and AEC are caused by heterozygous mutations in the transcription factor p63 encoded by TP63 . Here, we report a patient with an EEC/AEC syndrome‐like phenotype, including ankyloblepharon, ED, cleft palate, ectrodactyly, syndactyly, additional hypogammaglobulinemia, and growth delay. Neither pathogenic mutations in TP63 nor CNVs at the TP63 locus were identified. Exome sequencing revealed de novo heterozygous variants in CHUK (conserved helix‐loop‐helix ubiquitous kinase), PTGER4, and IFIT2 . While the variant in PTGER4 might contribute to the immunodeficiency and growth delay, the variant in CHUK appeared to be most relevant for the EEC/AEC‐like phenotype. CHUK is a direct target gene of p63 and encodes a component of the IKK complex that plays a key role in NF‐κB pathway activation. The identified CHUK variant (g.101980394T>C; c.425A>G; p.His142Arg) is located in the kinase domain which is responsible for the phosphorylation activity of the protein. The variant may affect CHUK function and thus contribute to the disease phenotype in three ways: (1) the variant exhibits a dominant negative effect and results in an inactive IKK complex that affects the canonical NF‐κB pathway; (2) it affects the feedback loop of the canonical and non‐canonical NF‐κB pathways that are CHUK kinase activity‐dependent; and (3) it disrupts NF‐κB independent epidermal development that is often p63‐dependent. Therefore, we propose that the heterozygous CHUK variant is highly likely to be causative to the EEC/AEC‐like and additional hypogammaglobulinemia phenotypes in the patient presented here.